[The use of the Sinemet-CR preparation in treating Parkinson's disease]

Sinemet-CR is manufactured by "Merck, Sharp and Dohme" firm (USA). It is represented the tablet form of drug that consists of levodopa (200 mg) and carbidopa (50 mg) on polymeric basis. This basis is dissolved gradually in small intestine providing prolonged drug's action. 29 patients in the age of 38-77 years with different forms of Parkinson's disease (1-13 years of duration) were treated using the doses 500-1500 mg. The doses depended upon both disease stage and individual sensitivity. It was also taken into consideration if the patients were or were not treated with levodopa and carbidopa preparations previously (the dose was adjusted during 3-4 weeks). The treatment's duration was 3 months. The positive medical effect was revealed in 23 cases (80%) while more expressed and firm effect was obtained in 15 cases. The most manifested action was observed toward rigidity, hypokinesia and tremor as well as toward such functions as memory, attention and psychical activity. Preparation's negative action was registered in 6 observations. In conclusion the authors noted both the high effectiveness and safety of preparation and recommended it for wide application.